The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech ...

Jersey Mike’s reveals how modern IPOs transfer risk to investors while insiders exit. Why IPOs are liquidity events, not ...

Market uncertainty is slowing IPO activity, with many offerings being canceled or paused in April. However, I think the strong start to the year, before the market tumbled, leaves room for optimism.

As the global business community converges at Davos, we are seeing powerful catalysts driving M&A and capital markets activity. The foundational drivers that accelerated business activity in the ...